Drug Profile
Research programme: optide therapeutics - Blaze Bioscience/Fred Hutchinson Cancer Research Center
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Blaze Bioscience; Fred Hutchinson Cancer Research Center
- Class Peptides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 03 Jul 2013 Early research in Cancer in USA (unspecified route)